Lay Title: A Study Assessing the Safety of a new drug (MGC018) in Patients with Solid Tumors
Technical Title: A Phase 1/2, First-in-Human, Open-Label Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) in Patients with Advanced Solid Tumors
Disease Types: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (contact study team directly for details regarding NSCLC & TNBC cohorts)
Basic information: The purpose of this study is to evaluate the safety of a new drug, MGC018, a monoclonal antibody with an active chemotherapy drug attached to it. MGC018 is made to attach to a protein called B7-H3, which is expressed at high levels on certain cancer cells. By attaching to cancer cells, MGC018 delivers the chemotherapy drug to the cancer cell. MGC018 is an intravenous (into the vein) treatment.
Research Procedures (not a complete list): During screening, you will have an electrocardiogram, echocardiogram, CT scan, Bone scan and lab work. Once you begin treatment, you will need to come to clinic every 3 weeks for the duration of your participation in the study. You will also need to return for scans every 9 weeks for the duration of the study.
Eligibility Criteria (not a complete list):
For More Detailed Information, Contact:
ClinicalTrials.gov Identifier: NCT03729596